Transforming Global Health with Fearless Science.
EpiVax has been pushing the boundaries of computational immunology for over 25 years, developing broad analytical capabilities that empower pharmaceutical developers to make informed decisions during the preclinical journey of their biologic therapeutics and vaccines. The goal is to aid in the development of treatments that are safer and more effective by offering cutting-edge in silico and in vitro methods.
We believe in the power of science to transform human and animal health outcomes globally. Our industry-leading tools are complemented by an expert team of scientists who bring decades of experience and a collaborative mindset to every project. This combination of expertise and innovation allows us to deliver unparalleled insights and solutions to our clients.
Our clients range from emerging startups to the largest players in the industry who are united by a common mission: improving patient care. We frequently collaborate with regulatory agencies, academia, and leading pharmaceutical companies to ensure that our contributions to science are impactful.
The philosophy of EpiVax is captured in the motto we live by, “Fearless Science.” This phrase represents our commitment to advancing science boldly and bravely, regardless of the challenges we face. It means daring to pursue groundbreaking research and development that has the potential to improve human and animal health across the world. We invite you to join us on this journey towards a healthier future, where science knows no limits.
Corporate Responsibility
At EpiVax, we aspire to see beyond the horizon and contribute to something greater than ourselves. To achieve this, we empower every team member to actively participate in building that legacy.
We believe that it is our common responsibility to support the community in which we live and work. Therefore, EpiVax and our team members regularly provide charitable support to local, national and international non-profits financially and through volunteer hours. In 2023, we contributed to more than 25 different organizations in our city and across the world in areas such as animal welfare, disaster recovery, homelessness and food insecurity, the arts, and more. Our dedication to giving back further emphasizes our commitment to improving the lives of others, whether it be through vaccination, therapeutics, or by lending a hand to our neighbors.
Leadership
Anne De Groot, M.D.
Founder & CSO
Anne De Groot, M.D.
Annie De Groot is internationally known for her research on the human immune system’s response to vaccines and therapeutics. She graduated from Smith College in 1978 and earned her medical degree at University of Chicago in 1983. After internal medical residency, she obtained advanced training in immunoinformatics and vaccinology with Michael Good, Russell Howard and Jay Berzofsky at the National Institutes of Health, and then returned for a fellowship in ID at New England Medical Center.
Senior Professor (Research), University of Georgia Center for Vaccines and Immunology Founder/Scientific Director GAIA Vaccine Foundation Volunteer Medical Director Clínica Esperanza /Hope Clinic. She then moved to Brown University, establishing the TB/HIV Research Lab as an emerging center for immune-informatics driven Vaccine design. EpiVax spun out from that laboratory in 1998 and she gradually shifted her effort from 20% to 80% effort at the company. In 2008, she was invited to move her academic affiliation from Brown University to University of Rhode Island, in order to establish the Institute for Immunology and Informatics (iCubed). In 2020, Dr. De Groot joined the University of Georgia as a Senior Professor (Research) in the College of Veterinary Medicine/Center for Vaccines and Immunology. She has been the recipient of many awards for her groundbreaking work at the intersection of immunology and informatics and is recognized as an early adopter of this technology and an evangelist for the use of immunoinformatics to improve vaccines and protein therapeutics.
William Martin
Founder, CIO & CTO
William Martin
William Martin is a co-founder and longtime employee of EpiVax.
He is trained in Economics and Business Administration, System Analysis, and Computational Immunology.
In his current role Mr. Martin serves as the Chief Information Officer (CIO) of EpiVax where Mr. Martin takes primary responsibility for setting information management policies.
Operational teams reporting to Mr. Martin are responsible for systems administration, software products development, and advanced technology development.
Rich-Henry Schabowsky, Ph.D., J.D.
CEO
Rich-Henry Schabowsky, Ph.D., J.D.
Rich-Henry has recently joined EpiVax leadership as Chief Executive Officer. His extensive experience and diverse skill set make him an outstanding choice for the CEO position, promising to drive innovation and growth.
Rich-Henry holds a bachelor’s degree in economics, a master’s and Ph.D. in Microbiology and Immunology, as well as a J.D. Starting his career as a researcher in vaccine development, he later became a partner and registered patent attorney at Dinsmore & Shohl LLP, specializing in IP protection for life science, biotech, and tech companies.
Joining EpiVax in 2021 as the Scientific and Intellectual Property Director, he spearheaded the company’s IP strategy for protecting immunoinformatics tools and therapeutics developed therefrom. More recently, he took on the role of partner at Thursday Ventures, a venture firm investing in early-stage frontier technology. He also recently served as CEO of Thursday’s talent acquisition firm, Towerhill Associates.
Beyond his corporate endeavors, Rich-Henry is actively involved in community service, serving on the board of Clínica Esperanza/Hope Clinic and teaching Brazilian jiu-jitsu to youth in his local community.
Christine Boyle, Ph.D.
Chief Scientific Operations Officer
Christine Boyle, Ph.D.
Christine is the Chief Scientific Operations Officer at EpiVax where she provides leadership to the research programs and project management, facilitating operations within the preclinical scientific teams. Christine earned her PhD in Immunology and Virology from the University of Massachusetts Medical School in 2000 and graduated from Smith College in 1990. She joined EpiVax in 2011, as a project manager in the Vaccine group where she managed multiple grant and internally funded programs, and collaborations focusing on T-cell epitope-driven vaccine development using EpiVax.
As Senior Director of Scientific Operations, she currently oversees and manages the complex scientific portfolio at EpiVax and anticipates the group’s future needs to develop capabilities aligned with the needs and vision of the senior leadership team. She provides guidance and oversight to scientific teams for the administration, development and preparation of research proposals and contracts that continue to grow EpiVax’ impressive grant portfolio and scientific discovery. Through her leadership, she builds an environment to empower and enable scientific team members to contribute to and invest in group success by building teams across functions with individuals who have the right skills and experience to deliver on key organizational initiatives. She is a skilled problem solver able to identify, evaluate, develop, recommend and/or negotiate novel solutions to meet critical project needs.
Brad Crevier, J.D.
CFO
Brad Crevier, JD
Brad is responsible for managing all strategic and operational financial objectives at EpiVax. His most recent financial management experience was as Assistant Treasurer at audio technology company Sonos, where he oversaw the team responsible for all operational treasury aspects of the public company. He also held the positions of Director of Treasury and Director of International Tax and was part of the team that brought the company public. Additionally, Brad has previous experience at private equity owned The Rockport Group and the Boston offices of Deloitte and PwC. He is a bar-certified attorney with a JD and MS Accounting/MBA from Northeastern University.
As a senior global finance executive, Brad brings deep expertise in corporate and capital structuring, finance policy implementation, treasury operations, tax strategy, and risk management across diverse business landscapes.
Amy Rosenberg, M.D.
Sr. Director of Immunology & Protein Therapeutics
Amy Rosenberg, M.D.
Amy Rosenberg is a physician immunologist with extensive expertise in development and immunogenicity of therapeutic protein and cellular products. During her 30+ years at the FDA, Amy was principal or intimately involved in the regulation and approval of numerous FDA regulated products. Amy joined EpiVax in September 2021.
During her time at the FDA, Amy oversaw the regulation of many therapies, including hematopoietic stem cells and their selection devices, therapeutic proteins including monoclonal antibodies and fusion proteins, enzyme replacement therapies, immunomodulators including interleukins and interferons, hematologic and somatic cell growth factors, and combination devices-biologics. Additionally, Amy served on the FDA’s Oncology Center of Excellence Science Council. Amy was also an FDA consultant to the Immune Tolerance Network (NIAID) and to the ABIRISK consortium. At EpiVax, Amy is a wealth of knowledge for clients looking to address immunogenicity risk in anticipation of regulatory filing. She now heads up the EpiVax TEA consulting service (Trusted Expert Advice) and provides consulting to clients on a one-on-one basis on relevant aspects of the FDA regulatory process as it relates to the client’s pipeline and projects.
Guilhem Richard, Ph.D.
Head of Innovation & Technology
Guilhem Richard, Ph.D.
Guilhem is the Head of Innovation and Technology at EpiVax, Inc. and has over 10 years of experience in computational immunology and vaccinology. Dr. Richard joined the EpiVax immunoinformatics team in 2014, developing new models for understanding the interaction between the immune system and protein sequences, while supporting EpiVax’s commercial and research programs. He spearheaded the development of a new computational platform for the development of personalized, neoantigen-based cancer vaccines (Ancer), and conducted subsequent translational work at EpiVax’s subsidiary company, EpiVax Therapeutics, Inc., where he served as Chief Scientific Officer/Chief Technology Officer from 2019 to 2024. Dr. Richard has been leading innovation efforts at EpiVax since 2024 and is overseeing the development of its next generation of immunoinformatics tools. Dr. Richard holds a Ph.D. in Bioinformatics from Boston University and a M.Eng. in Bioinformatics and Modeling from the National Institute of Applied Sciences (INSA) of Lyon, France.
Brian Roberts, Ph.D.
Director of Preclinical Immunology
Brian Roberts, Ph.D.
Brian is the scientific director of the Preclinical Immunology program. Dr. Roberts received his PhD in Cell and Molecular Biology from the University of Vermont in 2012. His research in the laboratory of Dr Sally Huber focused on the role of toll-like receptors in sex differences in viral-induced autoimmune myocarditis. Dr. Roberts joined EpiVax in 2015 as a postdoctoral researcher working primarily with the Tregitope team. In 2018 he became manager of the Protein Therapeutics group at EpiVax, and oversees the PANDA projects.
Aimee Mattei, M.S.
Director of Immunoinformatics
Aimee Mattei M.S.
Aimee manages a team of analysts and project managers providing in silico immunogenicity risk assessments supporting research, collaborative, and commercial projects.
She leads the development of novel in silico methods and tools for assessing immunogenic risk of peptide impurities, including sequences containing unnatural amino acids. She holds an M.S. in Pharmaceutical Chemistry and has previous experience in the design, synthesis, purification, and characterization of peptides supporting research programs from concept assessment through lead optimization in the endocrinology and oncology therapeutic areas.
Matthew Ardito
Director of IT
Matthew Ardito
In his early years at EpiVax, Matthew Ardito assisted in maintaining applications associated with the design and reengineering of protein therapeutics and antibody structures, as well as genome mining, epitope mapping, and vaccine design. In 2016, Matt was promoted to Principal Applications Developer and Codebase Manager, where he led a team of developers in the design, development, implementation, testing, and deployment of immunoinformatics applications. In 2021, Matt was promoted again to Director of IT, where he is responsible for the management, strategy, and execution related to the maintenance of IT infrastructure at EpiVax.
Sarah Moniz
Director of Business Development & Marketing
Sarah Moniz
Sarah is the Associate Director of Business Development at EpiVax, where she oversees the activities of the business development team (including sales, marketing, customer success) and manages key internal and external relationships. She has been with the company for six years. Having originally started in a junior role as a Sales & Marketing Associate and stepping into positions of increasing responsibility, Sarah’s experience and knowledge has grown over her time with EpiVax, resulting in a comprehensive understanding of EpiVax services and the various business development roles, which has enabled her to now lead and grow the team.
Leaya Martelli
Director of Human Resources
Leaya Martelli
As Director of Human Resources at EpiVax, Leaya enjoys being a strategic partner to the executive suite and all levels across EpiVax. Leaya is a department of one, and is responsible for employee development and engagement, compensation modeling and planning, benefit plan design, talent acquisition/recruiting, performance management, training and policy development, and succession planning.
Leaya started her career in recruiting, where she gained a valuable understanding of people management, business skills, communication, and patience. She later went on to start her own life science boutique recruitment firm, Place Boston, with two other women for nearly a decade. Leaya was later recruited by a former client to help develop a new start-up company, combining tech and life science recruitment, with a matching algorithm. Once the company, Clora, was fully established and had received Series A funding, Leaya transitioned into working directly for a life science company and has been with EpiVax since then. Leaya has a passion for helping others and her goal is to help businesses and employees in the life science industry expand, while advocating for both the company and the employees.
Leaya has a bachelor’s degree in business administration from Dean College with a concentration in Human Resources, and an additional certificate in Human Resource Management.